New pill targets Hard-to-Treat cancers with RAS mutations
Disease control
Recruiting now
This study tests a new oral drug called JYP0015 in people with advanced solid tumors (such as pancreatic, lung, or colorectal cancer) that have a RAS mutation. The drug aims to block the activity of the mutated RAS protein, which drives cancer growth. The trial will enroll 210 pa…
Phase: PHASE2 • Sponsor: Guangzhou JOYO Pharma Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC